Update: Temple Health and Keystone First Family Health Plans have reached a new contract agreement. 

Learn More
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

view all Clinical Trials

Overview

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Clinical Trial Information

Protocol

TIRB# 30807

Phase

3

Condition(s)

Chronic Cough

Investigator

Sean Duffy, MD

Coordinator

Kriti Mittal

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough